The prefilled syringes market is projected to grow at an annualized rate of ~5%, till 2030
Roots Analysis has done a detailedstudy on Prefilled Syringes, covering keyaspects of the industry’s evolution and identifying potential future growthopportunities.
Toorder this 800+ page report, which features 800+ figures and 150+ tables,please visit https://www.rootsanalysis.com/reports/view_document/prefilled-syringes-market/284.html
Key Market Insights
§ Presently, around 80types of prefilled syringes are available in the market, and several companiesclaim to be engaged in the manufacturing of both glass and plastic variants ofsuch versatile drug delivery solutions
§ Over 140 drugs and vaccines have either been marketed or have undergoneclinical investigation (since 2013) for delivery via prefilled syringesfor the treatment of a variety of disease indications
§ In order to gain acompetitive edge in the market, prefilled syringe manufacturers are activelyengaged in developing patient friendly products, with improved safety featuresand solutions
§ The market is also characterized by the presence of many contractservice providers, spread across the world, offering fill / finish services inprefilled syringes
§ Several big pharma companies are actively engaged in strengthening theirpipeline of injectable drugs across various therapeutic areas
§ An evaluation of 280+ marketed and pipeline products revealed that avariety of drugs / product candidates are likely to be considered foradministration via prefilled syringes in the near future, paving way for newpartnerships
§ The current market opportunity is well distributed across differenttherapeutic areas, molecule types and geographical regions; the market islikely to grow at a steady pace over the coming years
§ Glass, single chamber prefilled syringes dominate the current market;however, the demand for plastic devices is anticipated to witness a relativelyhigher growth in the foreseen future
For more information, please visit https://www.rootsanalysis.com/reports/view_document/prefilled-syringes-market/284.html
Table of Contents
1. PREFACE
1.1. Chapter Overview
1.2. Scope of the Report
1.3. Research Methodology
1.4. Chapter Outlines
2. EXECUTIVE SUMMARY
3. INTRODUCTION TO PREFILLED SYRINGES
3.1. Chapter Overview
3.2. History of Prefilled Syringes
3.3. Benefits of Prefilled Syringes Over TraditionalInjectable Devices
3.3.1. Benefits for Healthcare Professionals and End Users
3.3.2. Benefits to Manufacturers
3.3.3. Shift from Existing Dosage Forms to PrefilledSyringes
3.4. Prefilled Syringe Components
3.5. Classification of Prefilled Syringes
3.5.1. Classification by Barrel Fabrication Material
3.5.1.1. Glass
3.5.1.1.1. Limitations of Glass Barrel Prefilled Syringes
3.5.1.1.2. Addressing the Limitations of Glass BarrelPrefilled Syringes
3.5.1.2. Plastic
3.5.1.2.1. Limitations of Plastic Barrel Prefilled Syringes
3.5.1.2.2. Addressing the Limitations of Plastic BarrelPrefilled Syringes
3.5.1.2.3. Factors Likely to Drive the Use of PlasticBarrel Prefilled Syringes
3.5.2. Classification by Number of Chambers in the Barrel
3.5.3. Classification by Type of Needle System
3.5.4. Classification by Type of Packaging
3.6. Critical Attributes of Prefilled Syringe Design
3.7. Manufacturing Prefilled Syringes
3.7.1. Production of Barrels
3.7.1.1. Glass Barrel Prefilled Syringes
3.7.1.2. Plastic Barrel Prefilled Syringes
3.7.2. Production of Syringes
3.7.3. Barrel Siliconization
3.7.4. Syringe Sterilization
3.7.5. Validation of Sterilization
3.7.6. Syringe Filling
3.7.7. Syringe Testing
3.8. Future of Prefilled Syringes
4 PREFILLED SYRINGES: MARKET OVERVIEW
4.1. ChapterOverview
4.2. PrefilledSyringes: List of Available / Under Development Devices
4.2.1. Analysis byType of Barrel Fabrication Material
4.2.2. Analysis byNumber of Barrel Chambers
4.2.3. Analysis byType of Needle System
4.2.4. Analysis byDevice Capacity
4.3. PrefilledSyringes: List of Developers
4.3.1. Analysis byYear of Establishment
4.3.2. Analysis byCompany Size
4.3.3. Analysis byGeographical Location of Headquarters
4.3.4. Analysis byGeographical Location of Manufacturing Facilities
4.4. Technological Developments in Prefilled Syringes
5 PRODUCT COMPETITIVENESS ANALYSIS
5.1. ChapterOverview
5.2. Methodology
5.3. Assumptions andKey Parameters
5.4. ProductCompetitiveness Analysis: Prefilled Syringe Systems
5.4.1. Glass BarrelPrefilled Syringes
5.4.2. PlasticBarrel Prefilled Syringes
6 MANUFACTURERS OF PREFILLED SYRINGES
6.1. Chapter Overview
6.2. Key Prefilled Syringe Manufacturers Based in NorthAmerica
6.2.1. Becton Dickinson
6.2.1.1. Company Overview
6.2.1.2. Financial Performance
6.2.1.3. Prefilled Technology Solutions
6.2.1.4. Glass Barrel Prefilled Systems
6.2.1.4.1. BD Hypak Prefilled Syringe
6.2.1.4.2. BD Neopak Prefilled Syringe
6.2.1.4.3. BD Hylok Prefilled Syringe
6.2.1.5. Plastic Barrel Prefilled Systems
6.2.1.5.1. BD Sterifill Syringe Systems
6.2.1.6. Other Prefilled Delivery Systems
6.2.1.6.1. BD Uniject
6.2.1.7. Recent Developments
6.2.1.8. Future Outlook
6.2.2. West Pharmaceutical
6.2.2.1. Company Overview
6.2.2.2. Financial Performance
6.2.2.3. Prefilled Technology Solutions
6.2.2.4. Plastic Barrel Prefilled Systems
6.2.2.4.1. Daikyo Crystal Zenith Polymer RTU PrefilledSyringe
6.2.2.5. Drug Reconstitution Systems
6.2.2.6. Recent Developments
6.2.2.7. Future Outlook
6.3. Key Prefilled Syringe Manufacturers Based in Europe
6.3.1. Gerresheimer
6.3.1.1. Company Overview
6.3.1.2. Financial Performance
6.3.1.3. Prefilled Technology Solutions
6.3.1.4. Glass Barrel Prefilled Systems
6.3.1.4.1. Gx Glass Syringes
6.3.1.5. Plastic Barrel Prefilled Systems
6.3.1.5.1. ClearJect Prefilled syringes
6.3.1.5.2. Gx RTF Clearject Needle Syringe
6.3.1.6. Safety Syringes
6.3.1.6.1. Gx InnoSafe Safety Syringes
6.3.1.7. Self-Injection Devices
6.3.1.8. Recent Developments
6.3.1.9. Future Outlook
6.3.2. Ompi
6.3.2.1. Company Overview
6.3.2.2. Financial Performance
6.3.2.3. Glass Barrel Prefilled Systems
6.3.2.3.1. EZ-Fill Syringes
6.3.2.3.1.1. EZ-fill Fina
6.3.2.3.1.2. EZ-fill Nexa
6.3.2.3.1.3. EZ-fill Alba
6.3.2.4. Recent Developments
6.3.2.5. Future Outlook
6.3.3. Schott
6.3.3.1. Company Overview
6.3.3.2. Financial Performance
6.3.3.3. Glass Barrel Prefilled Syringes
6.3.3.3.1. syriQ Glass Syringes
6.3.3.4. Plastic Barrel Prefilled Syringes
6.3.3.4.1. TopPac Polymer Syringes
6.3.3.5. Recent Developments
6.3.3.6. Future Outlook
6.4. Key Prefilled Syringe Manufacturers in Asia
6.4.1. Nipro (Acquired MGlas)
6.4.1.1. Company Overview
6.4.1.2. Financial Performance
6.4.1.3. Glass Barrel Prefilled Systems
6.4.1.4. Recent Developments
6.4.1.5. Future Outlook
6.4.2. WEGO Prefills Pharmaceutical Packaging
6.4.2.1. Company Overview
6.4.2.2. Financial Performance
6.4.2.3. WeGo Glass Prefilled Syringe
6.4.2.4. Weigao Prefilled Flush Syringes
6.4.2.5. Future Outlook
6.4.3. Taisei Kako
6.4.3.1. Company Overview
6.4.3.2. Glass Barrel Prefilled Systems
6.4.3.2.1. VF-Syringe
6.4.3.2.1. SIN-Syringe
6.4.3.3. Plastic Barrel Prefilled System
6.4.3.3.1. ClearJect Syringes
6.4.3.3.2. FULJECT Passive Type Syringe
6.4.3.3.3. Ajex Needleless Injection System
6.4.3.4. Future Outlook
6.4.4. Terumo
6.4.4.1. Company Overview
6.4.4.2. Financial Performance
6.4.4.3. Plastic Barrel Prefilled Syringe
6.4.4.4. Safety Devices: Add-On Devices
6.4.4.5. Recent Developments
6.4.4.6. Future Outlook
6.5. Other Manufacturers
6.5.1. Aguettant
6.5.1.1. Company Overview
6.5.1.2. Prefilled Syringe Portfolio
6.5.1.2.1. Aguettant Prefilled Syringe
6.5.1.3. Recent Developments
6.5.2. Arte
6.5.2.1. Company Overview
6.5.2.2. Prefilled Syringe Portfolio
6.5.2.2.1. Dual Chamber Prefillable Syringe
6.5.2.2.2. Single Chamber Prefillable Syringe
6.5.3. J.O. Pharma (Subsidiary of Otsuka Holdings)
6.5.3.1. Company Overview
6.5.3.2. Prefilled Syringe Portfolio
6.5.4. Pfizer Injectables
6.5.4.1. Company Overview
6.5.4.2. Prefilled Syringe Portfolio
6.5.4.2.1. ABBOJECT Syringe
6.5.4.2.2. Emergency Syringes
6.5.4.2.3. iSecure Syringe System
6.5.5. Shandong Pharmaceutical Glass
6.5.5.1. Company Overview
6.5.5.2. Prefilled Syringe Portfolio
6.5.6. Shandong Zibo Minkang Pharmaceutical packing
6.5.6.1. Company Overview
6.5.6.2. Prefilled Syringe Portfolio
6.5.7. Vetter Pharma
6.5.7.1. Company Overview
6.5.7.2. Prefilled Syringe Portfolio
6.5.7.2.1. Lyo-Ject Glass Prefilled Syringe
6.5.7.2.2. Vetter-Ject Safety Device
6.5.7.2.3. V-OVS Safety Device
6.5.7.3. Recent Developments
7 NEEDLESTICK INJURIES
7.1. Chapter Overview
7.2. Incidence and Associated Financial Burden
7.3. Government Legislations for Prevention of NeedlestickInjuries
7.4. Safety Mechanisms Used in Modern Prefilled Syringes
7.4.1. Safety Systems: Add-On Safety Device Manufacturers
7.4.1.1. Becton Dickinson
7.4.1.2. Catalent
7.4.1.3. Terumo
7.4.1.4. Tip-Top
7.4.1.5. West Pharmaceutical
7.4.2. Safety Systems: Integrated Safety DeviceManufacturers
7.4.2.1. Gerresheimer
7.4.2.2. Injecto
7.4.2.3. MedicalChain International
7.4.2.4. OMPI
7.4.2.5. Owen Mumford
7.4.2.6. SHL Group
7.4.2.7. Taisei Kako
8 REGULATORY LANDSCAPE FOR PREFILLED SYRINGES
8.1. Chapter Overview
8.2. Regulatory Approval of Combination Products in the US
8.2.1. Overview
8.2.2. Historical Background
8.2.3. Regulatory Bodies and their Role in Product Approval
8.2.4. Regulatory Approval for Prefilled Syringes
8.3. Regulatory Approval of Combination Products in Europe
8.3.1. Overview
8.3.2. Regulatory Bodies and their Role in Product Approval
8.3.3. Regulatory Approval for Prefilled Syringes
8.4. Regulatory Approval of Combination Products in Canada
8.4.1. Overview
8.4.2. Regulatory Bodies and their Role in Product Approval
8.4.3. Regulatory Approval for Prefilled Syringes
8.5. Regulatory Approval of Combination Products in Brazil
8.5.1. Overview
8.5.2. Regulatory Bodies and their Role in Product Approval
8.5.3. Regulatory Approval for Prefilled Syringes
8.6. Regulatory Approval of Combination Products in Mexico
8.6.1. Overview
8.6.2. Regulatory Bodies and their Role in Product Approval
8.6.3. Regulatory Approval for Prefilled Syringes
8.7. Regulatory Approval of Combination Products inArgentina
8.7.1. Overview
8.7.2. Regulatory Bodies and their Role in Product Approval
8.7.3. Regulatory Approval for Prefilled Syringes
8.8. Regulatory Approval of Combination Products inAustralia
8.8.1. Overview
8.8.2. Regulatory Bodies and their Role in Product Approval
8.8.3. Regulatory Approval for Prefilled Syringes
8.9. Regulatory Approval of Combination Products in Japan
8.9.1. Overview
8.9.2. Regulatory Bodies and their Role in Product Approval
8.9.3. Regulatory Approval for Prefilled syringes
8.10. Regulatory Approval of Combination Products in China
8.10.1. Overview
8.10.2. Regulatory Bodies and their Role in ProductApproval
8.10.3. Regulatory Approval for Prefilled syringes
8.11. Regulatory Approval of Combination Products in India
8.11.1. Overview
8.11.2. Regulatory Bodies and their Role in ProductApproval
8.11.3. Regulatory Approval for Prefilled Syringes
8.12. Regulatory Approval of Combination Products in SouthKorea
8.12.1. Overview
8.12.2. Regulatory Bodies and their Role in ProductApproval
8.12.3. Regulatory Approval for Prefilled Syringes
8.13. Regulatory Approval of Combination Products in SaudiArabia
8.13.1. Overview
8.13.2. Regulatory Bodies and their Role in ProductApproval
8.13.3. Regulatory Approval for Prefilled Syringes
8.14. Regulatory Approval of Combination Products in UnitedArab Emirates
8.14.1. Overview
8.14.2. Regulatory Bodies and their Role in ProductApproval
8.14.3. Regulatory Approval for Prefilled Syringes
9 PREFILLED SYRINGE COMBINATION PRODUCTS: MARKET OVERVIEW
9.1. Chapter Overview
9.2. Prefilled Syringe Combination Products: List ofApproved Drugs, 2013-2019
9.2.1. Analysis by Type of Drug Molecule
9.2.2. Analysis by Approval Year
9.2.3. Analysis by Route of Administration
9.2.4. Analysis by Target Therapeutic Area
9.2.5. Prefilled Syringe Combination Products: AdditionalInformation
9.2.5.1. Analysis by Dose Strength
9.2.5.2. Analysis by Other Approved Dosage Forms
9.3. Prefilled Syringe Combination Products: List ofClinical Stage Drugs, 2013-2019
9.3.1. Analysis by Type of Drug Molecule
9.3.2. Analysis by Phase of Development
9.3.3. Analysis by Route of Administration
9.3.4. Analysis by Target Therapeutic Area
9.4. Prefilled Syringe Combination Products: List ofDevelopers
9.4.1. Analysis by Yearof Establishment
9.4.2. Analysis byCompany Size
9.4.3. Analysis byGeographical Location of Headquarters
9.5. Leading Drugs in Prefilled Syringes
9.6. Other Drugs Available in Prefilled Syringes
9.7. Popular Drugs in Prefilled Syringes: Case Studies
9.7.1. HUMIRA® (Adalimumab), AbbVie / Eisai
9.7.1.1. Target Indications and Available Dosage Forms
9.7.1.2. Shift from Vials to Syringes
9.7.2. Enbrel® (Etanercept), Amgen / Pfizer / Takeda
9.7.2.1. Target Indications and Available Dosage Forms
9.7.2.2. Shift from Vials to Syringes
10 KEY THERAPEUTIC AREAS
10.1. Chapter Overview
10.1.1. Autoimmune Disorders
10.1.1.1. Approved Injectables
10.1.1.2. Biosimilars
10.1.2. Infectious Diseases
10.1.2.1. Antiviral Drugs
10.1.2.1.1. Approved Injectables
10.1.2.1.2. Biosimilars
10.1.2.2. Vaccines
10.1.2.2.1. Approved Injectables
10.1.3. Neurological Disorders
10.1.3.1. Approved Injectables
10.1.3.2. Biosimilars
10.1.4. Metabolic Disorders
10.1.4.1. Approved Injectables
10.1.4.2. Biosimilars
11 PREFILLED SYRINGES: LIKELY DRUG CANDIDATES ANDPARTNER ANALYSIS
11.1. Chapter Overview
11.2. Likely Drug Candidates
11.2.1. Methodologyand Key Parameters
11.3. Marketed Drug Candidates
11.3.1. Most LikelyCandidates for Delivery via Prefilled Syringes
11.3.2. LikelyCandidates for Delivery via Prefilled Syringes
11.3.3. Less LikelyCandidates for Delivery via Prefilled Syringes
11.3.4. Least LikelyCandidates for Delivery via Prefilled Syringes
11.4. Clinical Drug Candidates
11.4.1. Most LikelyCandidates for Delivery via Prefilled Syringes
11.4.2. LikelyCandidates for Delivery via Prefilled Syringes
11.4.3. Less LikelyCandidates for Delivery via Prefilled Syringes
11.4.4. Least LikelyCandidates for Delivery via Prefilled Syringes
11.5. PotentialStrategic Partners
11.5.1. Methodologyand Key Parameters
11.5.2. Opportunities in North America
11.5.2.1. MostLikely Partners for Prefilled Syringes Combination Product Development
11.5.2. 2. LikelyPartners for Prefilled Syringes Combination Product Development
11.5.2.3. LessLikely Partners for Prefilled Syringes Combination Product Development
11.5.2.4. LeastLikely Partners for Prefilled Syringes Combination Product Development
11.5.3. Opportunities in Europe
11.5.3.1. MostLikely Partners for Prefilled Syringes Combination Product Development
11.5.3.2. LikelyPartners for Prefilled Syringes Combination Product Development
11.5.3.3. LessLikely Partners for Prefilled Syringes Combination Product Development
11.5.3.4. LeastLikely Partners for Prefilled Syringes Combination Product Development
11.5.4. Opportunities in Asia-Pacific and Rest of the World
11.5.4.1. MostLikely Partners for Prefilled Syringes Combination Product Development
11.5.4.2. LikelyPartners for Prefilled Syringes Combination Product Development
11.5.4.3. LessLikely Partners for Prefilled Syringes Combination Product Development
11.5.4.4. LeastLikely Partners for Prefilled Syringes Combination Product Development
12 BIG PHARMA INITIATIVES: PREFILLED SYRINGE COMBINATIONPRODUCTS AND LIKELY CANDIDATES
12.1. ChapterOverview
12.2. Methodology
12.3. TopPharmaceutical Companies
12.3.1. Analysis byTherapeutic Area
12.3.1.1. AutoimmuneDisorders
12.3.1.2. InfectiousDiseases
12.3.1.3. Oncological Disorders
12.3.1.4. MetabolicDisorders
12.3.1.5. Neurological Disorders
12.3.1.6. Inflammatory Disorders
12.3.1.7. OrthopedicDisorders
12.3.1.8. Others
12.3.2. Analysis byType of Molecule
12.3.2.1. Antibodies
12.3.2.2. Vaccines
12.3.2.3. Proteins
12.3.2.4. Others
13 SPECIALTY PREFILLED SYRINGES
13.1. Chapter Overview
13.2. Prefilled Flush Syringes
13.2.1. Overview
13.2.2. Prefilled Flush Syringes Available in the Market
13.2.3. Advantages of Prefilled Flush Syringes
13.3. Prefilled Diluent Syringes
13.3.1. Overview
13.3.2. Lyophilized Drugs Available in Prefilled DiluentSyringes
13.3.3. Advantages of Prefilled Diluent Syringes
13.4. Contrast Agent Prefilled Syringes
13.4.1. Overview
13.4.2. Contrast Agents Available in Prefilled Syringes
13.4.3. Advantages of Contrast Agent Prefilled Syringes
14 RECENT DEVELOPMENTS AND APPLICATIONS OF PREFILLEDSYRINGES
14.1. Chapter Overview
14.2. Prefilled Syringes For Lyophilized Drugs
14.2.1. Prefilled Diluent Syringes
14.2.2. Prefilled Dual / Multi-Chamber Prefilled Syringes
14.2.2.1. Lyophilized Drugs Available in Dual /Multi-Chamber Prefilled Syringes
14.2.2.2. Prefilled Dual-Chambered Prefilled Pen Injectorsfor Lyophilized Drugs
14.3. Prefilled Syringes for Ophthalmic Delivery
14.4. Prefilled Syringes for Dermal Fillers
14.5. Multilayer Plastic Prefilled Syringes with OxygenBarrier
14.6. Prefilled Syringes with Low Particle Formation Risk
14.7. Lubrication Technology for Prefilled Syringes
14.8. Advances in Terminal Sterilization of PrefilledSyringes
14.8.1. Noxilizer’s Nitrogen Dioxide Sterilization Technology
14.9. Prefilled Syringe Usage Aids for patients andHealthcare Providers
15 MARKET SIZING AND OPPORTUNITY ANALYSIS
15.1. Chapter Overview
15.2. Scope and Methodology
15.3. Global Prefilled Syringes Market, 2020-2030
15.3.1. Prefilled Syringes Market: Distribution byTherapeutic Area
15.3.1.1. Prefilled Syringes Market: Autoimmune Disorders
15.3.1.2. Prefilled Syringes Market: Infectious Diseases
15.3.1.3. Prefilled Syringes Market: Neurological Disorders
15.3.1.4. Prefilled Syringes Market: Blood Disorders
15.3.1.5. Prefilled Syringes Market: Oncological Disorders
15.3.1.6. Prefilled Syringes Market: Psychiatric Diseases
15.3.1.7. Prefilled Syringes Market: Respiratory Disorders
15.3.1.8. Prefilled Syringes Market: CardiovascularDisorders
15.3.1.9. Prefilled Syringes Market: Metabolic Disorders
15.3.1.10. Prefilled Syringes Market: Ophthalmic Disorder
15.3.1.11. Prefilled Syringes Market: Orthopedic Disorders
15.3.1.12. Prefilled Syringes Market: Other Diseases
15.3.2. Prefilled Syringes Market: Distribution by Type ofSyringe Barrel Material
15.3.2.1. Prefilled Syringes Market: Glass Barrel PrefilledSyringes
15.3.2.2. Prefilled Syringes Market: Plastic BarrelPrefilled Syringes
15.3.3. Prefilled Syringes Market: Distribution by Type ofChamber System
15.3.3.1. Prefilled Syringes Market: Single ChamberPrefilled Syringes
15.3.3.2. Prefilled Syringes Market: Dual Chamber PrefilledSyringes
15.3.4. Prefilled Syringes Market: Distribution by Type ofDrug Molecule
15.3.4.1. Prefilled Syringes Market: Antibodies
15.3.4.2. Prefilled Syringes Market: Proteins
15.3.4.3. Prefilled Syringes Market: Peptides
15.3.4.4. Prefilled Syringes Market: Small Molecules
15.3.4.5. Prefilled Syringes Market: Vaccines
15.3.5. Prefilled Syringes Market: Distribution byGeography
15.3.5.1. Prefilled Syringes Market: North America
15.3.5.2. Prefilled Syringes Market: Europe
15.3.5.3. Prefilled Syringes Market: Asia Pacific
15.3.5.4. Prefilled Syringes Market: Latin America
15.3.5.5. Prefilled Syringes Market: Middle East and Africa
15.3.6. Prefilled Syringes Market: Distribution bySpecialty Syringes
15.3.7. Prefilled Syringes Market for Autoimmune Disorders
15.3.7.1. Distribution by Syringe Barrel Material
15.3.7.1.1. Glass Barrel Prefilled Syringes
15.3.7.1.2. Plastic Barrel Prefilled Syringes
15.3.7.2. Distribution by Type of Chamber System
15.3.7.2.1. Single Chamber Prefilled Syringes
15.3.7.2.2. Dual Chamber Prefilled Syringes
15.3.7.3. Distribution by Type of Drug Molecule
15.3.7.3.1. Antibodies
15.3.7.3.2. Proteins
15.3.7.3.3. Small Molecules
15.3.7.4. Distribution by Geography
15.3.7.4.1. North America
15.3.7.4.2. Europe
15.3.7.4.3. Asia Pacific
15.3.7.4.4. Latin America
15.3.7.4.5. Middle East and Africa
15.3.8. Prefilled Syringes Market For Infectious Disorders
15.3.8.1. Distribution by Type of Syringe Barrel Material
15.3.8.1.1. Glass Barrel Prefilled Syringes
15.3.8.1.2. Plastic Barrel Prefilled Syringes
15.3.8.2. Distribution by Type of Chamber System
15.3.8.2.1. Single Chamber Prefilled Syringes
15.3.8.2.2. Dual Chamber Prefilled Syringes
15.3.8.3. Distribution by Type of Drug Molecule
15.3.8.3.1. Vaccines
15.3.8.4. Distribution by Geography
15.3.8.4.1. North America
15.3.8.4.2. Europe
15.3.8.4.3. Asia Pacific
15.3.8.4.4. Latin America
15.3.8.4.5. Middle East and Africa
15.3.9. Prefilled Syringes Market For NeurologicalDisorders
15.3.9.1. Distribution by Type of Syringe Barrel Material
15.3.9.1.1. Glass Barrel Prefilled Syringes
15.3.9.1.2. Plastic Barrel Prefilled Syringes
15.3.9.2. Distribution by Type of Chamber System
15.3.9.2.1. Single Chamber Prefilled Syringes
15.3.9.2.2. Dual Chamber Prefilled Syringes
15.3.9.3. Distribution by Type of Drug Molecule
15.3.9.3.1. Antibodies
15.3.9.3.2. Proteins
15.3.9.3.3. Peptides
15.3.9.4. Distribution by Geography
15.3.9.4.1. North America
15.3.9.4.2. Europe
15.3.9.4.3. Asia Pacific
15.3.9.4.4. Latin America
15.3.9.4.5. Middle East and Africa
15.3.10. Prefilled Syringes Market For Blood Disorders
15.3.10.1. Distribution by Type of Syringe Barrel Material
15.3.10.1.1. Glass Barrel Prefilled Syringes
15.3.10.1.2. Plastic Barrel Prefilled Syringes
15.3.10.2. Distribution by Type of Chamber System
15.3.10.2.1. Single Chamber Prefilled Syringes
15.3.10.2.2. Dual Chamber Prefilled Syringes
15.3.10.3. Distribution by Type of Drug Molecule
15.3.10.3.1. Proteins
15.3.10.3.2. Small Molecules
15.3.10.4. Distribution by Geography
15.3.10.4.1. North America
15.3.10.4.2. Europe
15.3.10.4.3. Asia Pacific
15.3.10.4.4. Latin America
15.3.10.4.5. Middle East and Africa
15.3.11. Prefilled Syringes Market For OncologicalDisorders
15.3.11.1. Distribution by Type of Syringe Barrel Material
15.3.11.1.1. Glass Barrel Prefilled Syringes
15.3.11.1.2. Plastic Barrel Prefilled Syringes
15.3.11.2. Distribution by Type of Chamber System
15.3.11.2.1. Single Chamber Prefilled Syringes
15.3.11.2.2. Dual Chamber Prefilled Syringes
15.3.11.3. Distribution by Type of Drug Molecule
15.3.11.3.1. Antibodies
15.3.11.3.2. Proteins
15.3.11.3.3. Peptides
15.3.11.3.4. Small Molecules
15.3.11.3.5. Vaccines
15.3.11.4. Distribution by Geography
15.3.11.4.1. North America
15.3.11.4.2. Europe
15.3.11.4.3. Asia Pacific
15.3.11.4.4. Latin America
15.3.11.4.5. Middle East and Africa
15.3.12. Prefilled Syringes Market For Metabolic Disorders
15.3.12.1. Distribution by Type of Syringe Barrel Material
15.3.12.1.1. Glass Barrel Prefilled Syringes
15.3.12.1.2. Plastic Barrel Prefilled Syringes
15.3.12.2. Distribution by Type of Chamber System
15.3.12.2.1. Single Chamber Prefilled Syringes
15.3.12.2.2. Dual Chamber Prefilled Syringes
15.3.12.3. Distribution by Type of Drug Molecule
15.3.12.3.1. Proteins
15.3.12.3.2. Peptides
15.3.12.4. Distribution by Geography
15.3.12.4.1. North America
15.3.12.4.2. Europe
15.3.12.4.3. Asia Pacific
15.3.12.4.4. Latin America
15.3.12.4.5. Middle East and Africa
15.3.13. Prefilled Syringes Market For Other Disorders
15.3.13.1. Distribution by Type of Syringe Barrel Material
15.3.13.1.1. Glass Barrel Prefilled Syringes
15.3.13.1.2. Plastic Barrel Prefilled Syringes
15.3.13.2. Distribution by Type of Chamber System
15.3.13.2.1. Single Chamber Prefilled Syringes
15.3.13.2.2. Dual Chamber Prefilled Syringes
15.3.13.3. Distribution by Type of Drug Molecule
15.3.13.3.1. Antibodies
15.3.13.3.2. Proteins
15.3.13.3.3. Peptides
15.3.13.3.4. Small Molecules
15.3.13.4. Distribution by Geography
15.3.13.4.1. North America
15.3.13.4.2. Europe
15.3.13.4.3. Asia Pacific
15.3.13.4.4. Latin America
15.3.13.4.5. Middle East and Africa
16 GROWTH DRIVERS
16.1. Chapter Overview
16.2. Rising Incidence of Chronic Diseases
16.3. Growing Preference for Self-Injection
16.4. Evolving Patient Demographics
16.5. Growth of Biologics and Biosimilars Market
16.6. Changing Pharmaceutical Strategies
16.7. Increasing Focus on Prevention of NeedlestickInjuries
16.8. Prefilled Syringes in Autoinjectors and Pen Injectors
17 SWOT ANALYSIS
17.1. Chapter Overview
17.2. Strengths
17.3. Weaknesses
17.4. Opportunities
17.5. Threats
17.6. Concluding Remarks
18 PREFILLED SYRINGE COMPONENT MANUFACTURERS
18.1. Chapter Overview
18.2. List of Component Manufacturers
18.3. Aptar Pharma (a Part of AptarGroup)
18.3.1. Company Overview
18.3.2. Financial Performance
18.3.3. Product Portfolio
18.3.4. Recent Developments and Future Outlook
18.4. West Pharmaceutical
18.4.1. Company Overview
18.4.2. Financial Performance
18.4.3. Product Portfolio
18.4.4. Recent Developments and Future Outlook
18.5. Datwyler Sealing Solutions (a Part of Datwyler Group)
18.5.1. Company Overview
18.5.2. Financial Performance
18.5.3. Product Portfolio
18.5.4. Recent Developments and Future Outlook
18.6. Lonstroff (a Part of Sumitomo Rubber Industries)
18.6.1. Company Overview
18.6.2. Financial Performance
18.6.3. Product Portfolio
18.6.4. Recent Developments and Future Outlook
18.7. Ompi (a Part of Stevanato Group)
18.7.1. Company Overview
18.7.2. Product Portfolio
18.7.3. Recent Developments and Future Outlook
18.8. Jiangsu Hualan Pharmaceutical New Material
18.8.1. Company Overview
18.8.2. Product Portfolio
18.8.3. Recent Developments and Future Outlook
19 FILL / FINISH SERVICE PROVIDERS FOR PREFILLED SYRINGES
19.1. Chapter Overview
19.2. Fill / Finish Processing of Prefilled Syringes
19.2.1. Steps Involved in Fill / Finish Process
19.2.2. Methods of Filling and Stoppering of PrefilledSyringes
19.2.3. Prefilled Syringe Filling Technologies
19.3. Outsourcing of Fill / Finish Operations
19.4. Growth Considerations
19.5. Prefilled Syringes: List of Fill / Finish ServiceProviders
19.5.1. Analysis by Year of Establishment
19.5.2. Analysis by Geographical Location of Headquartersand Type of Drug Molecule
19.5.3. Analysis by Scale of Operation
20 CASE STUDY: AUTOINJECTORS
20.1. Chapter Overview
20.2. Autoinjectors: Market Overview
20.3. Key Players
20.3.1. Elcam Medical (E3D Elcam Drug Delivery Devices)
20.3.1.1. Company Overview
20.3.1.2. Product Portfolio
20.3.2. Nuance Designs
20.3.2.1. Company Overview
20.3.2.2. Product Portfolio
20.3.3. Owen Mumford
20.3.3.1. Company Overview
20.3.3.2. Product Portfolio
20.3.4. Scandinavian Health Limited (SHL) Group
20.3.4.1. Company Overview
20.3.4.2. Product Portfolio
20.3.5. Union Medico
20.3.5.1. Company Overview
20.3.5.2. Product Portfolio
20.3.6. Ypsomed
20.3.6.1. Company Overview
20.3.6.2. Product Portfolio
21 CONCLUDING REMARKS
21.1. Chapter Overview
21.2. Key Takeaways
22 INTERVIEW TRANSCRIPTS
22.1. Chapter Overview
22.2. Oval Medical Technologies
22.2.1. Company Snapshot
22.2.2. Interview Transcript: Matthew Young, Founder andChief Technology Officer
22.3. Intas Pharmaceuticals
22.3.1. Company Snapshot
22.3.2. Interview Transcript: Kirti Maheshwari, ChiefTechnical Officer
22.4. IDT Biologika
22.4.1. Company Snapshot
22.4.2. Interview Transcript: Gregor Kawaletz, ChiefCommercial Officer
22.5. West Pharmaceutical
22.5.1. Company Snapshot
22.5.2. Interview Transcript: Kevin Cancelliere and TiborHlobik, Marketing Directors
22.6. Lonstroff
22.6.1. Company Snapshot
22.6.2. Interview Transcript: Marco Pederiva, Marketing andSales Directors
22.7. IDEO
22.7.1. Company Snapshot
22.7.2. Interview Transcript: Jesse Fourt, Design Directors
22.8. Small-sized Medical Device Company
22.8.1. Interview Transcript: Anonymous, Chief ExecutiveOfficer
23 APPENDIX 1: TABULATED DATA
24 APPENDIX 2: LIST OF COMPANIES
Contact Details
Gaurav Chaudhary
+1 (415) 800 3415
